NEW YORK (GenomeWeb) – BioSequence has embarked on a year-long study of OncoDNA's OncoDeep CUP service in Spain, looking to raise the profile of the genomic offering among clinicians, and to strengthen its case for reimbursement.
With a population of 46 million, Spain is one of Europe's larger markets, and one where the adoption of the cancer of unknown primary test could translate into adoption in neighboring Portugal, as well as in Latin America, a region that Valencia-based BioSequence also serves.